Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Dupixent is already approved to treat a range of inflammatory diseases including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, making $6 billion in global sales last ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...